Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Metastatic castration-resistant Prostate cancer (mCRPC) is a very late stage of prostate
cancer with poor prognosis. Although there are several treatment strategies available for
mCRPC, these drugs are not always effective for every patient. Also, it's still not clear
what's the best therapeutic choice for a certain group of patients.
In the previous works of the investigators, a subtype of prostate cancer, intraductal
carcinoma of the prostate (IDC-P) was studied. The investigators have reported in their two
published papers that, IDC-P is an adverse pathological type associated with rapid disease
progression. They also found in another study that, for patients with IDC-P, Abiraterone
seemed to have better treatment efficacy than Docetaxel-based chemotherapy as first-line
treatment for mCRPC, in terms of either PSA-response and PSA-progression free survival. So,
in this study, the investigators hope to design a prospective study to verify the predictive
ability of IDC-P in the first-line treatment of mCRPC.
With disease progression, the drug resistance will inevitably occur in all patients after the
treatment of CRPC. However, the exact mechanism of this process is not yet known. So, in this
study the investigators are also trying to explore some of the genes related to the treatment
efficacy by means of the next generation sequencing.